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Melioidosis, a disease caused by Burkholderia pseudomallei,
is endemic to Southeast Asia and northern Australia. Patients
with diabetes and chronic renal failure have a higher risk of
contracting melioidosis. Therapeutic approaches are tar-
geted at either the clinical resolution of acute infection
(acute phase) or the eradication of residual intracellular
infection to prevent relapse (maintenance phase). In Thai-
land, the first-line regimen in the acute phase is intravenous
ceftazidime with or without trimethoprim-sulfamethoxazole
(TMP-SMX). For maintenance therapy, a four-drug regimen
of chloramphenicol, doxycycline and TMP-SMX is recom-
mended. We report a case of persistent septicemic melioi-
dosis that failed to respond to ceftazidime plus TMP-SMX, but
subsequently gave a clinical response to meropenem and
surgical debridement.
A 56-year-old male Thai farmer with poorly controlled
diabetes mellitus was admitted to the hospital with a week-
long history of fever, chills and frontal headache. One month
earlier, he fell and hit his head on the floor near a chicken
coop. His headache was accompanied by painful swelling of
his forehead. On admission, physical examination revealed a
temperature of 39 8C, a blood pressure of 100/60 mmHg,
respiratory rate of 20/min, and a 3  4 cm fluctuated fore-
head mass with erythema, warmth and tenderness to palpa-
tion. His white blood cell count was 16.3  109/L (neutrophils
85%, lymphocytes 15%), whereas hemoglobin, blood chem-
istry, transaminases and chest roentgenogram were normal.
Gram stain of exudate from the forehead lesion showed
Gram-negative bacilli. Blood cultures and drainage cultures
grew B. pseudomallei. The patient was treated with cefta-
zidime (2 g every 8 hr) and TMP-SMX (160/800 mg every 8 hr).
Based on the Clinical and Laboratory Standards Institute
(CLSI) disk diffusion interpretative guidelines for Acineto-
bacter spp.,1 this isolate was susceptible to ceftazidime,
TMP-SMX, imipenem, meropenem and doxycycline. On hos-
pital day six, he developed a right lower lung infiltrate and
rapidly progressive swelling, erythema and fluid-filled bleb of
the right leg. Ultrasound of the abdomen showed no evidence
of liver and splenic abscesses. Transthoracic echocardiogram
demonstrated no vegetation. The patient underwent surgical
debridement of the right leg for presumptive necrotizing
fasciitis; tissue cultures were obtained. Bacteremia persisted
despite the seven-day treatment course of ceftazidime and1201-9712/$36.00 # 2009 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.11.018TMP-SMX. Tissue cultures subsequently grew B. pseudomallei
with a similar susceptibility pattern to the previous isolate.
Using the E-test method (AB Biodisk, Sweden), minimal
inhibitory concentrations (MICs) of ceftazidime, imipenem
andmeropenemwere 4, 1 and 0.5 mg/ml, respectively. Based
on the MIC results, meropenem was initiated; ceftazidime
and TMP-SMX were discontinued. Over the next week, the
patient steadily improved clinically and was discharged on
doxycycline and TMP-SMX to complete the 24-week course.
The patient had full resolution of his illness at a three-month
follow-up after completion of therapy.
Several reasons favor the use of ceftazidime with or
without TMP-SMX as the first-line treatment of melioidosis
in Thailand. First, according to national surveillance on anti-
microbial susceptibility to B. pseudomallei during 2000—
2005, more than 99% of B. pseudomallei isolates were sus-
ceptible to ceftazidime.2 Second, although several antibio-
tics have been studied for the treatment of melioidosis, none
have shown superiority to ceftazidime with or without TMP-
SMX.3—5 Third, ceftazidime and TMP-SMX are inexpensive
relative to alternative regimens. Carbapenems have some
speculative benefits over ceftazidime, given that they are
more active in vitro,6,7 display a post-antibiotic effect8 and
have been associated with decreased endotoxin release.6 In a
time-kill study, carbapenems Exhibit 99% bactericidal activ-
ity within four hours.7 In this case, switch to a carbapenem
was associated with clinical improvement after six days of
failed ceftazidime therapy. The addition of TMP-SMX to
ceftazidime was well tolerated, but was not shown to reduce
mortality in a recent study.9 Although controversial, the
potential advantages of combining TMP-SMX with ceftazi-
dime include the intracellular activity of TMP-SMX and the
potential for reduced risk of emergence of antimicrobial
resistance.2 We acknowledge that the potential benefit of
granulocyte colony-stimulating factor (GCSF) in this case
remains speculative. A recent study in Australia suggested
a reduction in mortality associated with GCSF treatment of
patients in septic shock due to melioidosis, whereas an ear-
lier clinical trial in Thailand showed no survival benefit.10
In conclusion, we suggest that patients with melioidosis
who do not respond to ceftazidime with or without TMP-SMZ
should undergo a thorough work-up inclusive of abdominal
ultrasound, echocardiogram and MIC values of selected
antibiotics. If there is no evidence of specific organ infection
or abscess, an alternative antibiotic should be considered
based on MIC results. This case of disseminated melioidosisPublished by Elsevier Ltd. All rights reserved.
e332 Letter to the Editoroccurred while the patient was on ceftazidime with
TMP-SMX, highlighting the role of carbapenems as an alter-
native in patients who are allergic or not responding
to ceftazidime with or without TMP-SMZ.
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